Related Experiment Videos
Tinzaparin as an antithrombotic: an overview
1Department of Haematology, Birmingham Heartlands Hospital.
Hospital Medicine (London, England : 1998)
|November 3, 1998
Summary
Tinzaparin, a low molecular weight heparin, offers effective once-daily subcutaneous treatment for deep venous thrombosis and pulmonary embolism without requiring lab monitoring. It was the first LMWH approved for pulmonary embolism in 1997.
Area of Science:
- Pharmacology
- Thrombosis Treatment
- Anticoagulation Therapy
Background:
- Low molecular weight heparins (LMWHs) represent advancements in anticoagulant therapy.
- Tinzaparin is an LMWH administered subcutaneously.
- Established efficacy in treating deep venous thrombosis (DVT).
Purpose of the Study:
- To highlight the therapeutic applications of tinzaparin.
- To underscore its role in managing pulmonary embolism (PE).
- To emphasize its convenience regarding laboratory monitoring.
Main Methods:
- Subcutaneous administration of tinzaparin.
- Clinical evaluation for efficacy in DVT and PE.
- Assessment of need for laboratory monitoring.
Main Results:
- Tinzaparin demonstrates effectiveness in treating DVT.
- Tinzaparin received licensing for pulmonary embolism treatment in November 1997.
- No routine laboratory monitoring is required for tinzaparin therapy.
Conclusions:
- Tinzaparin is a convenient and effective LMWH for DVT and PE.
- Its once-daily subcutaneous dosing simplifies treatment protocols.
- Tinzaparin offers a valuable therapeutic option in anticoagulation.